SCHEMBL6337243

SCHEMBL6337243

O=C(O)Cc1ccc(Oc2ccc3cc(OCc4ccccc4)ccc3c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 3/20 0.59
FFAR1 O14842 5/20 0.56
FFAR4 Q5NUL3 3/20 0.56
SRD5A2 P31213 2/20 0.56
RXRA P19793 1/20 0.56
RXRB P28702 1/20 0.56
RXRG P48443 1/20 0.56
NR3C1 P04150 1/20 0.53
MEN1 O00255 1/20 0.53
POLB P06746 1/20 0.53
PPARG P37231 1/20 0.53
KMT2A Q03164 1/20 0.53
NCOA2 Q15596 1/20 0.53
NCOA1 Q15788 1/20 0.53
NCOA3 Q9Y6Q9 1/20 0.53
MRGPRX4 Q96LA9 1/20 0.53
NPC1 O15118 1/20 0.52
MAPT P10636 1/20 0.52
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6341082 0.90 FFAR1 (0.68) ALOX5FFAR1FFAR4SRD5A2NR3C1
SCHEMBL6235731 0.86 SRD5A2 (0.64) FFAR1SRD5A2NR3C1MEN1POLB
SCHEMBL6239573 0.86 FFAR1 (0.76) FFAR1FFAR4SRD5A2NR3C1
SCHEMBL10605167 0.85 ALOX5 (0.76) ALOX5FFAR1FFAR4MEN1KMT2A
SCHEMBL1066614 0.85 FFAR1 (0.70) ALOX5FFAR1FFAR4SRD5A2CYP1A2
SCHEMBL6341556 0.84 ALOX5 (0.51) ALOX5FFAR1FFAR4SRD5A2RXRA
SCHEMBL6342568 0.84 NR4A2 (0.71) ALOX5SRD5A2RXRARXRBRXRG
Hydrochloric Acid SCHEMBL10622121 0.83 FFAR1 (0.68) ALOX5FFAR1FFAR4SRD5A2CYP1A2
SCHEMBL4222632 0.83 FFAR1 (0.68) ALOX5FFAR1FFAR4SRD5A2CYP1A2
Ammonia Solution, Strong SCHEMBL27788257 0.83 FFAR1 (0.68) ALOX5FFAR1FFAR4SRD5A2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 ALOX5 620/4885FFAR1 1564/4885FFAR4 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.